387 related articles for article (PubMed ID: 11676620)
1. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs.
Lautzenhiser SJ; Fialkowski JP; Bjorling D; Rosin E
Res Vet Sci; 2001 Jun; 70(3):239-41. PubMed ID: 11676620
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones.
Gottlieb S; Wigney DI; Martin PA; Norris JM; Malik R; Govendir M
Aust Vet J; 2008 Apr; 86(4):147-52. PubMed ID: 18363989
[TBL] [Abstract][Full Text] [Related]
3. Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro.
Brothers AM; Gibbs PS; Wooley RE
Vet Ther; 2002; 3(4):493-500. PubMed ID: 12584687
[TBL] [Abstract][Full Text] [Related]
4. [Investigation of the effect of efflux pump inhibitors to MIC values of ciprofloxacin in clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Acinetobacter baumannii and Staphylococcus aureus].
Cetinkaya E; Coban AY; Durupinar B
Mikrobiyol Bul; 2008 Oct; 42(4):553-61. PubMed ID: 19149076
[TBL] [Abstract][Full Text] [Related]
5. Mutation rate of avian intestinal coliform bacteria when pressured with fluoroquinolones.
Medders WM; Wooley RE; Gibbs PS; Shotts EB; Brown J
Avian Dis; 1998; 42(1):146-53. PubMed ID: 9533092
[TBL] [Abstract][Full Text] [Related]
6. Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections.
Cooke CL; Singer RS; Jang SS; Hirsh DC
J Am Vet Med Assoc; 2002 Jan; 220(2):190-2. PubMed ID: 12126128
[TBL] [Abstract][Full Text] [Related]
7. [Studies on pyridonecarboxylic acids as antibacterial agents. XII. Synthesis and antibacterial activity of 6-chloro-1-cyclopropyl-7-(1-piperazinyl)-1, 4-dihydro-4-oxo-quinoline-3-carboxylic acid and analogues].
Li XH; Tian ZM; Miao H; Yu LX; Guo HY
Yao Xue Xue Bao; 1997 Nov; 32(11):844-51. PubMed ID: 11596203
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections.
Meinen JB; McClure JT; Rosin E
Am J Vet Res; 1995 Sep; 56(9):1219-24. PubMed ID: 7486402
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice.
Tomii Y; Ozaki M; Matsuda M; Honmura T; Nishimura I; Yamaguchi R; Adachi T; Okawa Y; Nishino T
Arzneimittelforschung; 1996 Dec; 46(12):1169-73. PubMed ID: 9006794
[TBL] [Abstract][Full Text] [Related]
10. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
11. Comparative quantification of the in vitro activity of veterinary fluoroquinolones.
Grobbel M; Lübke-Becker A; Wieler LH; Froyman R; Friederichs S; Filios S
Vet Microbiol; 2007 Sep; 124(1-2):73-81. PubMed ID: 17498893
[TBL] [Abstract][Full Text] [Related]
12. Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998).
Oluoch AO; Kim CH; Weisiger RM; Koo HY; Siegel AM; Campbell KL; Burke TJ; McKiernan BC; Kakoma I
J Am Vet Med Assoc; 2001 Feb; 218(3):381-4. PubMed ID: 11201564
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of antimicrobial resistance in fecal Escherichia coli isolates from stray pet dogs and hospitalized pet dogs in Korea.
Nam HM; Lee HS; Byun JW; Yoon SS; Jung SC; Joo YS; Lim SK
Microb Drug Resist; 2010 Mar; 16(1):75-9. PubMed ID: 20192822
[TBL] [Abstract][Full Text] [Related]
14. Ciprofloxacin as a representative of disk diffusion in vitro susceptibility of enrofloxacin for bacterial organisms from the middle-ear tissue of dogs with end-stage otitis externa.
Cole LK; Kwochka KW; Hillier A; Kowalski JJ; Smeak DD; Kelbick NT
Vet Dermatol; 2006 Apr; 17(2):128-33. PubMed ID: 16515655
[TBL] [Abstract][Full Text] [Related]
15. Development of antimicrobial drug resistance in rectal Escherichia coli isolates from dogs hospitalized in an intensive care unit.
Ogeer-Gyles J; Mathews KA; Sears W; Prescott JF; Weese JS; Boerlin P
J Am Vet Med Assoc; 2006 Sep; 229(5):694-9. PubMed ID: 16948576
[TBL] [Abstract][Full Text] [Related]
16. Questions study on Escherichia coli susceptibility.
Goering RV
J Am Vet Med Assoc; 2002 Apr; 220(8):1139; author reply 1139-41. PubMed ID: 11990957
[No Abstract] [Full Text] [Related]
17. In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine.
Bennie CJ; To JL; Martin PA; Govendir M
Aust Vet J; 2015; 93(1-2):40-5. PubMed ID: 25622709
[TBL] [Abstract][Full Text] [Related]
18. Detection of fluoroquinolone resistance level in clinical canine and feline Escherichia coli pathogens using rapid real-time PCR assay.
Shaheen BW; Wang C; Johnson CM; Kaltenboeck B; Boothe DM
Vet Microbiol; 2009 Nov; 139(3-4):379-85. PubMed ID: 19596530
[TBL] [Abstract][Full Text] [Related]
19. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin.
Prescott JF; Yielding KM
Can J Vet Res; 1990 Jan; 54(1):195-7. PubMed ID: 2306672
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas.
Ganière JP; Médaille C; Limet A; Ruvoen N; André-Fontaine G
Vet Dermatol; 2001 Jun; 12(3):171-5. PubMed ID: 11420933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
